作者認為，隻有係統治療會延長乳腺癌柔腦膜轉移患者的生存期。放射治療和鞘內療法雖然可改善患者症狀和體征，但對存活期無益。
該項前瞻性觀察研究共納入149例乳腺癌柔腦膜轉移的女性患者。作者分別評估了係統治療和局部療法對患者的療效，發現采用不同的治療方案，隻有係統治療可延長患者存活期。局部療法，無論是放射治療還是藥物化療(鞘內注射甲氨蝶呤或阿糖胞苷脂質體)僅可提升生活質量，但不能延長存活期。
作者認為，隻有係統治療會延長乳腺癌柔腦膜轉移患者的生存期。放射治療和鞘內療法雖然可改善患者症狀和體征，但對存活期無益。
TAKE-HOME MESSAGE
This is a prospective observational study of 149 women with metastatic breast cancer with leptomeningeal involvement. The authors evaluated systemic therapy versus local therapy in the management of these patients. They found that, among the different treatment options, systemic therapy was the only option to prolong survival. Local therapy either with radiation or chemotherapy (intrathecal methotrexate or liposomal cytarabine) improved quality of life but not survival.
The authors conclude that only systemic therapy resulted in prolonged survival in patients with leptomeningeal metastasis. While both radiation therapy and lumbar intrathecal therapy improved signs and symptoms, survival did not improve.
Clinical Breast Cancer
Breast Cancer Leptomeningeal Metastasis: The Results of Combined Treatment and the Comparison of Methotrexate and Liposomal Cytarabine as Intra-CSF Chemotherapy
我要跟帖copyright©醫學論壇網 版權所有，未經許可不得複製、轉載或鏡像
京ICP證120392號 京公網安備110105007198 京ICP備10215607號-1 （京）網藥械信息備字（2022）第00160號
